Sol Langermann
CIK: 0001775459
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NXTC
NextCure, Inc.
Officer
Discretionary Trading P&L
Holdings
About Langermann Sol
Langermann Sol (SEC CIK 0001775459) files insider reports with the SEC as Chief Scientific Officer of NextCure, Inc. (NXTC).
Signal8 holds 1 ownership filing by Langermann Sol, a Form 4, filed on Feb 3, 2025. Those filings report 1 transaction, the latest on Jan 31, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Langermann Sol's filings is in BELTSVILLE, MD.
Recent filings by Langermann Sol
- Jan 31, 2025: Grant or award of NXTC derivative securities (Form 4, code A).
Other insiders filing for NextCure, Inc. (NXTC)
- ADAR1 Capital Management, LLC, 10% Owner
- Simcere Zaiming, Inc., Officer
- Feigal Ellen, Director
- Jones Elaine V, Director
- Borgman Anne Elizabeth, Director
- Webster Stephen W, Director